Gaugene Announces ￥32M in Series A Funding Round

According to VCBeat, recently, Beijing Zhizhen Biotechnology Co., Ltd ("Gaugene") has announced its Series A financing of nearly RMB100 million, led by Shanghai-based Sharewin Investment, together with Beijing E-Town Innovation Equity Investment and its existing investor Highlight Capital. Gaugene will use the proceeds to expand the fluorescence & flow cytometry-based pipeline, improve its production capacity and accelerate the commercialization of products.

Prior to this, Gaugene completed its angel round in 2018 and Pre-A rounds in 2019.

Founded in 2017 and located in Beijing Economic and Technological Development Zone, Gaugene is a high-tech company dedicated to providing excellent hematological detection instruments, reagents and services for in vitro diagnostic (IVD) users.

Since its establishment of three years, Gaugene gradually built several propriety platforms including the magnetic fluorescence-encoded microspheres platform, fluorescence labeling platform for protein, multispectral fluorescence imaging platform and automated magnetic cell separation platform. Gaugene has formed a product line of flow fluorescence immunoassay and blood infection for joint inspection of a variety of indicators in clinical diagnosis.

For specific application scenarios, Gaugene plans to provide specialized diagnostic solutions to help clients improve their service capabilities, such as a series of tests in reproductive medicine for men and women, covering semen quality, hormone level, ovarian status assessment, and immune assessment.

Sharewin Investment is an equity investment company with industrial funds. Its current business covers VC, PE, PIPE, industry merger and acquisition, etc. It focuses on the investment in healthcare, TMT, new materials & advanced manufacturing, and cultural media & consumption.

HLC is a health industry focused fund. It is dedicated to investing in leading life science enterprises that provide innovative products and services to advance diagnosis and treatment of diseases and to promote healthy living. With extensive experience, the company has established a strong presence across sub-sectors such as biotechnology (innovative therapeutics, CRO/CMO, etc.), medical technology (medical devices, IVD, etc.) and consumer health (hospital chains, personal care, etc.).